Continuous‐flow techniques for platelet concentrate collection: A step toward standardization and yield predictability

Abstract

This study chronicles leukocyte- and erythrocyte-depleted platelet concentrate collection by a dual stage channel in which three variables: 1) donor peripheral blood platelet concentration, 2) total blood processed, and 3) collection volume were statistically correlated with platelet yield as determined by a multiple regression analysis of single variables. Platelet concentration in the final yield was related to donor precount and collection rate, and could be varied as indicated for individual applications. Total blood processed was established by procedure time, which in turn was defined by citrate-induced calcium changes in the donor. Reduction in peripheral blood platelet concentration averaged 24% for a mean platelet yield of 3.8 X 10(11). An average of 40% of transfused platelet concentrates were recovered in recipient peripheral blood 1 hr posttransfusion and were hemostatically effective, as determined by correction of bleeding time. Platelet yields and patient response were sustained during current collection procedures, verifying the principles described during the investigative period.

Modeling of platelet concentrate yield in continuous‐flow cell separation devices

“…While the focus of their paper was directed toward lymphocyte contamination of the platelet concentrates, the calculation results from reported preprocedure platelet counts (250 k 90 x lO'/liter), the number of cycles performed (usually seven or eight), and the formula provided to compute the total blood processed, suggest that, with the surge method, 36% of circulating platelets were removed during harvesting and 44 % when the red cell methods were employed. Ogata et al [8] also reported that yield in the Haemonetics is related to preprocedure platelet count and the "blood drawing time," which is an indirect reflection of the total blood processed. Standardizing data collection for platelet collection procedures from all methods of preparation of platelet concentrates might offer the means by which instrument and procedure modifications could be accomplished to improve platelet yields.…”

Phase II Study of Prophylactic Non-Irradiated Granulocyte Transfusions in AML Patients Receiving Induction Chemotherapy

“…Since the development of plasmapheresis technology and transfusion medicine in the 1950s [6,7], spontaneous hemorrhage as a primary cause of mortality from treatment-related myelosuppression has decreased, and infectious complications remain the leading cause of morbidity and mortality in children and adults with acute leukemia [8][9][10]. The degree and duration of neutropenia are predictive, with high-risk patients considered to be those with prolonged (>7 days duration) and profound (absolute neutrophil count (ANC) <100 cells/mm 3 ) neutropenia [11].…”